{{search.results.count}} results {{searchFilter()}} {{searchQuery()}}

RECOMMENDED {{ searchResult.published_at }}

{{search.results.count}} results {{searchFilter()}} {{searchQuery()}}

{{ item.title }}

{{ item.short_summary }}

{{ em.name }}{{ $last ? '' : ',' }}

Enter a search term such as “mobile analytics” or browse our content using the filters above.

No_results

That’s not only a poor Scrabble score but we also couldn’t find any results matching “”.
Check your spelling or try broadening your search.

Logo_distressed

This service is currently undergoing maintenance.
Please try again later.

Google bans ads for controversial drug

Avatar-blank-50x50
1 comment

Google has announced it will ban online advertisements for an appetite suppressant that has come under fire in medical circles.

The search giant contacted some advertisers to inform them it would stop taking ads for ephedrine-based products "in the coming weeks".

The drug can also be used as a stimulant, concentration aid and decongestant and is often used in bodybuilding.

But doses were severely restricted under 1997 US legislation. Side effects can include angina, sweating, nausea, insomnia, confusion and pulmonary edema, according to British Medical Association documentation.

Despite the dangers, it is thought many people still buy large quantities of the drugs via online adverts.

One online marketer who had advertised ephedrine and received Google's notification wrote:

"It actually surprises me that it took this long for Google to make the move. Oh well, it was fun while it lasted."

Google last month added free-to-play gambling sites to its list of outlawed ads in its AdWords content policy.

Avatar-blank-50x50

Published 13 July, 2007 by Robert Andrews

243 more posts from this author

1 comment
Google, Strategy & Operations

Comments (1)

Avatar-blank-50x50

Efosa

Hmmm, only God knows the next aspect of publishers to be banned by Google.

over 8 years ago

Comment
No-profile-pic
Save or Cancel
Daily_pulse_signup_wide

Enjoying this article?

Get more just like this, delivered to your inbox.

Keep up to date with the latest analysis, inspiration and learning from the Econsultancy blog with our free Daily Pulse newsletter. Each weekday, you ll receive a hand-picked digest of the latest and greatest articles, as well as snippets of new market data, best practice guides and trends research.